Trial Condition(s):

Contraception, Heavy menstrual bleeding

Induction of CYP3A4 by rifampin

Bayer Identifier:

91392

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-002617-36

EU CT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

March2005

May2005

Phase

Could I receive a placebo?

Products

Natazia/Qlaira (EV/DNG, BAY86-5027)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Locations
Locations Bayer Pharma AG Berlin, Germany, 13353	Contact Us: E-mail: [email protected] Phone: Not Available

Bayer Pharma AG

Berlin, Germany, 13353

Contact Us:

E-mail: [email protected]

Phone: Not Available

Contraception, Heavy menstrual bleeding

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

45 Years

65 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information